GeneDx Holdings Corp. (NASDAQ:WGS) Given Consensus Rating of “Moderate Buy” by Brokerages

GeneDx Holdings Corp. (NASDAQ:WGS) has been given an average recommendation of “Moderate Buy” by the nine ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $150.7143.

WGS has been the subject of a number of analyst reports. Wells Fargo & Company upgraded GeneDx from an “equal weight” rating to an “overweight” rating and set a $155.00 price target for the company in a report on Monday, February 9th. Canaccord Genuity Group boosted their target price on shares of GeneDx from $160.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Weiss Ratings restated a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, January 21st. BTIG Research dropped their price target on shares of GeneDx from $200.00 to $170.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Jefferies Financial Group set a $150.00 price objective on shares of GeneDx in a report on Monday.

Insider Activity at GeneDx

In other news, COO Bryan Dechairo sold 5,961 shares of the stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $85.70, for a total transaction of $510,857.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Katherine Stueland sold 10,857 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $143.89, for a total transaction of $1,562,213.73. Following the sale, the chief executive officer directly owned 14,237 shares of the company’s stock, valued at $2,048,561.93. The trade was a 43.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 30,961 shares of company stock valued at $3,933,831. Insiders own 29.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of WGS. Royal Bank of Canada grew its position in shares of GeneDx by 30.2% during the 1st quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock valued at $2,611,000 after buying an additional 6,840 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in GeneDx by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock valued at $677,000 after acquiring an additional 453 shares during the period. NewEdge Advisors LLC grew its holdings in shares of GeneDx by 270,700.0% during the first quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock valued at $240,000 after purchasing an additional 2,707 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of GeneDx by 67.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock valued at $2,500,000 after purchasing an additional 11,375 shares during the last quarter. Finally, AlphaQuest LLC raised its position in shares of GeneDx by 351.5% during the 2nd quarter. AlphaQuest LLC now owns 763 shares of the company’s stock worth $70,000 after purchasing an additional 594 shares during the period. 61.72% of the stock is currently owned by institutional investors.

GeneDx Stock Performance

NASDAQ:WGS opened at $79.71 on Friday. The firm’s fifty day simple moving average is $106.45 and its 200 day simple moving average is $123.65. The company has a current ratio of 2.46, a quick ratio of 2.59 and a debt-to-equity ratio of 0.16. GeneDx has a twelve month low of $55.17 and a twelve month high of $170.87. The firm has a market capitalization of $2.30 billion, a price-to-earnings ratio of -106.28 and a beta of 2.00.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Monday, February 23rd. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.03. The firm had revenue of $120.99 million during the quarter, compared to the consensus estimate of $120.80 million. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%. As a group, equities research analysts expect that GeneDx will post 0.97 earnings per share for the current fiscal year.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.